Skip to content

Author

Karen Denning

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata: Final Results from BRAVE-AA1 and BRAVE-AA2

Long-term efficacy and safety data are imperative for therapies used to treat severe alopecia areata (AA) because the disease is chronic, loss of response can be devastating to patients, and the safety profile needs to support long-term therapy. Baricitinib, a selective JAK inhibitor, has been approved for severe AA in...

R. Vleugels, B. M. Piraccini, N. Mesinkovska et al. · 0 citations
Open access Nov 2026

Long-Term Safety of Baricitinib in Pediatric Patients With Atopic Dermatitis Aged 2 to <18 Years With Up to 5.2 Years of Exposure

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD...

A. Wollenberg, A. Torrelo, Masanori Ikeda et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.